Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 1877-1883

  Das, Jharna R ^a   Fryar, Elizabeth B ^a   Epie, Nicolas N ^a   Southerland, William M ^a   Bowen, Donnell ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

5 Fluorouracil; Methotrexate; Raloxifene

Indexed keywords

FLUOROURACIL; METHOTREXATE; RALOXIFENE; TRYPAN BLUE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FLOW CYTOMETRY; GROWTH RATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; BONE MARROW; BONE MARROW DISEASES; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; DRUG INTERACTIONS; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; METHOTREXATE; RALOXIFENE;

EID: 33745586582     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kaklamani VG and Gradishar WJ: Adjuvant therapy of breast cancer. Minerva Gynecol 57: 521-536, 2005.
2. Colleoni M, Price K, Castiglione-Gertsch M, Goldhirsch A, Coates A, Lindtner J, Collins J, Gelber RD, Thurlimann B and Rudenstam CM: Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer 34: 1693-1700, 1998.
3. Early Breast Cancer Trialists Collaborative Groups: Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an over view of randomized trials. Lancet 356: 1687-1717, 2005.
4. Lewis JS and Jordan VC: Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 597: 247-263, 2005.
5. Goldstein SR, Siddhanti S, Ciaccia AV and Plouffe L Jr: A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update 6: 212-224, 2000.
6. Jordan CV, Gapstur S and Morrow M: Selective estrogen receptor modulator and reduction of risk of breast cancer, osteoporosis and coronary heart disease. J Nat Cancer Inst 93: 1449-1457, 2001.
7. Bowen D, Johnson DH, Southerland WM, Hughes DE and Hawkins M: 5-Fluorouracil simultaneously maintains methotrexate antineoplastic activity in human breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Anticancer Res 19: 985-988, 1999.
8. Bowen D, Southerland WM, Johnson DH, Hawkins M Jr and Hughes DE: Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells. Cancer Detect Prev 24: 452-458, 2000.
9. White RM: 5-Fluorouracil modulates the toxicity of high dose methotrexate. J Clin Pharmacol 35: 1156-1165, 1995.
10. Desoto JA, Bowen D, Davis JH, Southerland WM and Hawkins M Jr: Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells. Anticancer Res 22: 1007-1009, 2002.
11. Fryar EB, Jharna RD, Davis JH, Desoto JA, Laniyan I, Southerland WM and Bowen D: Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human MCF-7 breast cancer cells: the importance of sequence in combination chemotherapy, Anticancer Res, in press, 2006.
12. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55-63, 1983.
13. Jolivet J, Schilsky RL, Bailey BD, Drake JC and Chabner BA: Synthesis retention, and biological activity of methotrexate polyglutamates in cultured human bone marrow. J Clin Invest 70: 351-360, 1982.
14. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC and Jolivet J: Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76: 907-912, 1985.
15. Koizumi S, Curt GA, Fine RL, Griffin JD and Chabner BA: Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 75: 1008-1014, 1985.
16. Sutherland RL, Green MD, Hall RE, Reddel RR and Taylor IW: Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 19: 615-621, 1983.
17. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.